Last Close
May 15  •  04:00PM ET
37.02
Dollar change
-1.68
Percentage change
-4.34
%
Index
RUT
P/E
-
EPS (ttm)
-4.17
Insider Own
7.54%
Shs Outstand
62.16M
Perf Week
-9.73%
Market Cap
2.32B
Forward P/E
-
EPS next Y
-3.12
Insider Trans
120.52%
Shs Float
57.86M
Perf Month
-8.39%
Enterprise Value
2.30B
PEG
-
EPS next Q
-0.96
Inst Own
86.24%
Perf Quarter
67.74%
Income
-230.66M
P/S
-
EPS this Y
13.38%
Inst Trans
12.87%
Perf Half Y
82.81%
Sales
0.00M
P/B
20.53
EPS next Y
16.69%
ROA
-76.39%
Perf YTD
32.40%
Book/sh
1.80
P/C
13.67
EPS next 5Y
41.69%
ROE
-208.80%
52W High
47.84 -22.62%
Perf Year
1011.71%
Cash/sh
2.71
P/FCF
-
EPS past 3/5Y
12.22% -8.23%
ROIC
-89.95%
52W Low
2.81 1217.39%
Perf 3Y
602.47%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
- -
Gross Margin
-
Volatility
8.24% 7.35%
Perf 5Y
-55.95%
Dividend TTM
-
EV/Sales
-
EPS Y/Y TTM
-15.28%
Oper. Margin
-
ATR (14)
3.24
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
3.54
Sales Y/Y TTM
-
Profit Margin
-
RSI (14)
40.28
Dividend Gr. 3/5Y
- -
Current Ratio
3.54
EPS Q/Q
13.70%
SMA20
-13.77%
Beta
2.25
Payout
-
Debt/Eq
1.39
Sales Q/Q
-
SMA50
0.53%
Rel Volume
0.76
Prev Close
38.70
Employees
124
LT Debt/Eq
1.29
SMA200
57.98%
Avg Volume
1.07M
Price
37.02
IPO
Oct 04, 2018
Option/Short
Yes / Yes
Trades
Volume
810,330
Change
-4.34%
Date Action Analyst Rating Change Price Target Change
May-11-26Upgrade Chardan Capital Markets Neutral → Buy $61
Nov-11-25Upgrade H.C. Wainwright Neutral → Buy $24
Oct-24-25Upgrade JP Morgan Neutral → Overweight $24
Sep-25-25Upgrade Barclays Underweight → Equal Weight $17
Sep-22-25Initiated Jefferies Buy $15
Aug-14-25Upgrade JP Morgan Underweight → Neutral $15
Dec-09-24Upgrade Jefferies Hold → Buy $20
Sep-05-24Initiated H.C. Wainwright Neutral $3
Dec-11-23Resumed Goldman Sell $2
Nov-17-23Upgrade CapitalOne Equal Weight → Overweight $7 → $12
May-07-26 04:00PM
May-01-26 12:23AM
Mar-31-26 04:45PM
Mar-27-26 08:23AM
Mar-26-26 06:46AM
06:00AM Loading…
06:00AM
Feb-06-26 11:31AM
Feb-04-26 07:00AM
Jan-07-26 08:19PM
Dec-30-25 08:45AM
Dec-22-25 10:11AM
Dec-18-25 08:26PM
Dec-16-25 10:55PM
Dec-15-25 04:01PM
Nov-14-25 07:36AM
04:05PM Loading…
Nov-13-25 04:05PM
Nov-12-25 05:48PM
Nov-05-25 07:00AM
Sep-15-25 07:00AM
Sep-12-25 11:30AM
Sep-02-25 08:00AM
Aug-29-25 03:05PM
Aug-26-25 07:52PM
Aug-19-25 02:18PM
Aug-14-25 11:41AM
Aug-13-25 04:00PM
Jul-10-25 08:00AM
Jun-25-25 04:45PM
Jun-24-25 05:51AM
Jun-13-25 11:30AM
09:32PM Loading…
May-29-25 09:32PM
May-15-25 11:04AM
May-14-25 04:15PM
May-01-25 11:43PM
Apr-01-25 09:35AM
Mar-28-25 09:45AM
Mar-27-25 04:01PM
Mar-26-25 03:58PM
Mar-10-25 04:39PM
Feb-04-25 07:30AM
Jan-13-25 04:26PM
Jan-07-25 06:00AM
Dec-09-24 09:18PM
12:33PM
Nov-25-24 09:55AM
Nov-14-24 04:01PM
Nov-11-24 06:15AM
Oct-14-24 05:35PM
Sep-23-24 06:00AM
Sep-17-24 04:05PM
Sep-13-24 11:30AM
Aug-16-24 10:42AM
Aug-14-24 09:54PM
04:01PM
Jul-10-24 12:00PM
Jun-20-24 08:23AM
Jun-14-24 11:30AM
May-29-24 04:36PM
May-16-24 12:51PM
May-15-24 10:55PM
04:01PM
May-14-24 07:31AM
May-13-24 07:32PM
May-02-24 04:30PM
Apr-04-24 12:09PM
Apr-01-24 05:04PM
12:00PM
Mar-29-24 10:36AM
Mar-28-24 11:53AM
08:32AM
06:30AM
Mar-26-24 06:15AM
Jan-30-24 06:30AM
Jan-04-24 04:15PM
Dec-14-23 11:30AM
Nov-21-23 04:15PM
Nov-15-23 08:00AM
Nov-14-23 06:09PM
04:01PM
Nov-06-23 05:00AM
Nov-01-23 11:21PM
Oct-17-23 01:44AM
Oct-11-23 06:00AM
Sep-13-23 11:30AM
Sep-08-23 06:00AM
Sep-07-23 06:00AM
Aug-16-23 10:26AM
Aug-14-23 07:31PM
04:01PM
08:34AM
07:15AM
Aug-02-23 10:09AM
Jul-27-23 02:30AM
Jul-26-23 06:42AM
Jul-25-23 09:16AM
Jul-24-23 06:26AM
06:09AM
06:00AM
Jun-14-23 11:30AM
May-30-23 04:15PM
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BORGESON JOHN A.Chief Financial OfficerApr 15 '26Option Exercise1.0428,61429,759211,930Apr 16 05:00 PM
BORGESON JOHN A.Chief Financial OfficerApr 02 '26Option Exercise1.0430,00031,200213,316Apr 02 08:26 PM
BORGESON JOHN A.Chief Financial OfficerApr 02 '26Sale39.9230,0001,197,488183,316Apr 02 08:26 PM
JOHN BORGESONOfficerApr 02 '26Proposed Sale42.8130,0001,284,300Apr 02 04:23 PM
PERLROTH VICTORChairman and CEOMar 25 '26Option Exercise1.04300,000312,0002,395,538Mar 27 06:08 PM
BAKER BROS. ADVISORS LPDirectorDec 18 '25Buy23.002,608,69660,000,00818,358,772Dec 19 04:06 PM
BORGESON JOHN A.See RemarksJun 17 '25Sale3.657232,640183,316Jun 17 08:15 PM